Physician profile
Gregory D Brooks
NPI 1134178817
$8,140.08
in general payments reported to CMS, 2019-2025
41 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $703 · 2021: $1,037 · 2022: $1,380 · 2023: $1,432 · 2024: $1,500 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.13 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,781.84 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $1,074.98 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $834.62 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Glaxosmithkline, LLC. | $575.03 | 2019-2025 | Trelegy Ellipta, Nucala |
| Pharming Healthcare, INC. | $503.85 | 2019-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $422.52 | 2021-2024 | Dupixent |
| Amgen INC. | $422.19 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $270.72 | 2021-2025 | Orladeyo |
| Csl Behring | $264.65 | 2022-2025 | Haegarda, Hizentra |
| Grifols USA, LLC | $259.84 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $246.26 | 2019-2025 | |
| Optinose US, INC. | $134.63 | 2019-2023 | |
| Blueprint Medicines Corporation | $122.95 | 2023-2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $109.81 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.90 | 2020-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $95.62 | 2019 | |
| Pfizer INC. | $86.83 | 2025 | |
| Leo Pharma INC. | $84.96 | 2023-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $73.33 | 2019-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Kaleo, INC. | $71.35 | 2021-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $50.59 | 2019-2023 | |
| Horizon Therapeutics Plc | $49.87 | 2019-2021 | |
| Verona Pharma, INC. | $47.46 | 2025 | Ohtuvayre |
| Octapharma USA, INC. | $47.33 | 2023 | Panzyga |
| Adma Biomanufacturing LLC | $42.88 | 2022 | |
| Cycle Pharmaceuticals INC | $34.05 | 2024-2025 | Sajazir |
| Seqirus USA INC | $32.55 | 2025 | Fluad, Flucelvax |
| Ionis Pharmaceuticals, INC. | $32.11 | 2025 | Dawnzera |
| Alk-Abello, INC | $30.84 | 2021-2022 | |
| Jubilant Hollisterstier LLC | $29.42 | 2019-2021 | |
| Mylan Specialty L.P. | $23.66 | 2020 | |
| Hospira, INC. | $21.66 | 2025 | |
| Aimmune Therapeutics, INC. | $21.47 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $18.88 | 2025 | Neffy |
| Circassia INC. | $17.53 | 2019 | |
| Lilly USA, LLC | $15.84 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $15.58 | 2025 | Nemluvio |
| Organon LLC | $3.48 | 2025 | Vtama |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.